Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) CFO Joseph Walter Vazzano sold 10,271 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $5.43, for a total value of $55,771.53. Following the completion of the transaction, the chief financial officer owned 557,504 shares in the company, valued at approximately $3,027,246.72. This trade represents a 1.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Joseph Walter Vazzano also recently made the following trade(s):
- On Tuesday, June 9th, Joseph Walter Vazzano sold 39,067 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.36, for a total value of $209,399.12.
Abeona Therapeutics Stock Performance
ABEO stock opened at $5.53 on Friday. The company has a market cap of $315.15 million, a P/E ratio of 5.70 and a beta of 1.35. Abeona Therapeutics Inc. has a 1 year low of $4.00 and a 1 year high of $7.54. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.89 and a quick ratio of 5.70. The stock’s fifty day moving average price is $5.42 and its 200-day moving average price is $5.17.
Hedge Funds Weigh In On Abeona Therapeutics
Several large investors have recently made changes to their positions in ABEO. Goldman Sachs Group Inc. lifted its position in shares of Abeona Therapeutics by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock valued at $954,000 after acquiring an additional 66,422 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Abeona Therapeutics by 129.1% in the second quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock valued at $6,282,000 after acquiring an additional 623,243 shares in the last quarter. Creative Planning lifted its position in shares of Abeona Therapeutics by 43.0% in the second quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock valued at $81,000 after acquiring an additional 4,305 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Abeona Therapeutics by 255.6% in the second quarter. JPMorgan Chase & Co. now owns 831,132 shares of the biopharmaceutical company’s stock valued at $4,721,000 after acquiring an additional 597,373 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in shares of Abeona Therapeutics in the second quarter valued at about $27,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the company. Stifel Nicolaus set a $17.00 target price on Abeona Therapeutics in a report on Tuesday, March 17th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Thursday, May 28th. Oppenheimer reaffirmed an “outperform” rating on shares of Abeona Therapeutics in a report on Monday, March 9th. Finally, Wall Street Zen raised Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Abeona Therapeutics presently has a consensus rating of “Hold” and an average target price of $19.00.
Check Out Our Latest Analysis on ABEO
Abeona Therapeutics Company Profile
Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.
The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Featured Articles
- Five stocks we like better than Abeona Therapeutics
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
